Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

Fact Check Friday: The truth about the cost of 340B to patients

January 26, 2018

Three ways 340B is currently leading to higher health care costs for Americans.

Read More

Ask About Adherence: Private-sector collaboration can lead to savings and care improvement

January 25, 2018

Medication non-adherence costs hundreds of billions of dollars each year and makes up 7 to 13 percent of all health spending in the U.S.

Read More

PhRMA launches new consumer-facing Let's Talk About Cost website

January 24, 2018

Today, as part of the Let's Talk About Cost campaign, PhRMA launched, a national consumer-facing website.

Read More

Guess what? Part B drug spending remains stable share of Medicare spending

January 23, 2018

In 2015, Part B drug spending grew modestly, but remained just 3 percent of total Medicare spending.

Read More

340B Spotlight: New pieces of legislation continue momentum to fix 340B program

January 18, 2018

Two new pieces of legislation have been introduced to increase oversight of and fix the 340B program.

Read More

PhRMA Statement on HELP ACT

January 17, 2018

Today, Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl provided the following statement.

Read More

PhRMA urges CMS to share the savings with seniors

January 17, 2018

Yesterday, PhRMA submitted comments in response to the Centers for Medicare & Medicaid Services (CMS) Request for Information (RFI).

Read More

PhRMA Statement on Comments to CMS Regarding Proposed Part D Rule and RFI Exploring Pass-Through Rebates to Seniors at Point of Sale

January 16, 2018

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments to the Centers for Medicare & Medicaid Services regarding the proposed rule, “Contract Year 2019 Policy and Technical Changes to the Medicare Advantage Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program.”

Read More

ICYMI: Why 2017 medicine approvals matter

January 12, 2018

The FDA just approved the highest amount of innovative new medicines in over 20 years.

Read More

Clarity around anti-kickback statute needed to promote innovative payment arrangements

January 10, 2018

The broad terms of the anti-kickback statute are limiting the number and scope of innovative results-based contracts; a safe harbor is needed.

Read More